Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Immediate Azathioprine (1st attack)

Phase 3

AAssistance Publique - Hôpitaux de Paris

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Acute Demyelinating SyndromeRecruiting

Acute Demyelinating SyndromePhase 3

Recruiting

Timeline

Expected Milestones

Q2 2030

Phase 3Recruiting

Acute Demyelinating Syndrome

NCT05545384

Clinical

Trials by Indication[1]

Acute Demyelinating Syndrome1 trial

Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-myelin Oligodendrocytes Glycoprotein (Anti-MOG) Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05545384·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Immediate Azathioprine (1st attack). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Immediate Azathioprine (1st attack). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Related News